Infections caused by protozoan parasites such as Chagas disease, human African trypanosomiasis, leishmaniasis, or malaria are responsible for considerable morbidity and mortality worldwide with devastating social and economic consequences (Table 1) [1]. Under normal circumstances (efficient epidemiological surveillance programs and sanitary education) the control of these diseases can be carried out effectively. Nevertheless, the implementation of an adequate health care system to palliate the necessities of the affected populations is hindered by the lack of financial and human resources, political instability in these countries, and often questionable government prioritization [2].

Currently, there is lack of effective, safe, and affordable therapies for the treatment of these diseases. The drugs used are far from ideal, and many of them were introduced decades ago; thus the development of new and more effective drugs with fewer side effects represents a crucial dare.

Over the last century, natural products have provided molecules with high structural diversity and "drug-like" properties from a physicochemical point of view. The reason resides in their chemical and steric complexity since they have well-defined three-dimensional structures, improved in terms of efficiency and selectivity for the molecular target [3, 4]. Natural product research has made a significant contribution to the chemotherapy of parasitic diseases such as quinine and artemisinin whose analogs are currently in use for the treatment of malaria.

This special issue brings significant works, done by leading scientists, and provides an overview on and an insight into recent advances that will contribute to the discovery of natural compounds with high potential against these protozoan parasites.

The readers will find, in nine papers, not only a wide range of topics including the identification of natural compounds with in vitro and in vivo activity against Trypanosoma cruzi, Plasmodium falciparum, or Leishmania spp. but also recent advances in the mechanism of action of bioactive compounds and the design of semisynthetic derivatives as new more effective chemotherapeutic agents with less toxicity.
Table 1: Protozoan infectious diseases.

<table>
<thead>
<tr>
<th>Parasites</th>
<th>Disease</th>
<th>Occurrence</th>
<th>Mortality</th>
<th>DALYs</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Plasmodium</em></td>
<td>Malaria</td>
<td>219 million new cases*</td>
<td>660,000 deaths*</td>
<td>33,976,000</td>
</tr>
<tr>
<td><em>Leishmania</em></td>
<td>Leishmaniasis</td>
<td>300,000 new cases of VL each year</td>
<td>Approx. 40,000 deaths due to VL</td>
<td>1,974,000**</td>
</tr>
<tr>
<td><em>Trypanosoma</em></td>
<td>Human African trypanosomiasis</td>
<td>20,000 actual cases</td>
<td>12,000</td>
<td>430,000**</td>
</tr>
<tr>
<td></td>
<td>Chagas disease</td>
<td>Approx. 8 million cases***</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

VL: visceral leishmaniasis, CL: cutaneous leishmaniasis, DALY’s: Disability Adjusted Life Years.


Acknowledgment

We are most grateful to the authors for their generous and timely response in spite of their research and academic responsibilities.

Liliana Muschietti
Roser Vila
Valdir Cechinel Filho
William Setzer

References


Submit your manuscripts at
http://www.hindawi.com